论文部分内容阅读
目的 探讨降纤酶治疗急性脑梗死的疗效和安全性。 方法 1 0 6例发病在 72 h内的急性脑梗死患者随机分成治疗组和对照组 ,两组患者年龄、性别、伴发疾病和既往史积分、治疗前神经功能缺损程度评分相似 ,具有可比性。治疗组给降纤酶 1 0 u静脉滴注 ,每天 1次 ;对照组给东菱精纯克栓酶 (DF-52 1 ) 1 0 IU静脉滴注 ,隔天 1次 ,7天为 1个疗程。动态监测血浆纤维蛋白原浓度 ,并进行疗效和安全性评价。 结果 降纤酶具有降低纤维蛋白原浓度 ,治疗急性脑梗死的总有效率为 92 .4 5% ,与 DF-52 1比较无显著性差异 (P >0 .0 5) ,无不良反应。 结论 降纤酶治疗急性脑梗死安全有效
Objective To investigate the efficacy and safety of defibrase in the treatment of acute cerebral infarction. Methods One hundred and six patients with acute cerebral infarction within 72 hours were randomly divided into treatment group and control group. The two groups were similar in age, gender, concomitant disease and past history scores, and the scores of neurological deficits before treatment were comparable and comparable . The treatment group to defibrase 10 intravenous drip once a day; the control group to Dongling Jing Keke pure enzyme (DF-52 1) 10 IU intravenous infusion, once every other day, 7 days for a Course of treatment. Dynamic monitoring of plasma fibrinogen concentration, and efficacy and safety evaluation. Results Defibrase had a decreased fibrinogen concentration. The total effective rate for treating acute cerebral infarction was 92.45%, which showed no significant difference compared with that of DF-52 1 (P> 0.05). There was no adverse reaction. Conclusion Defibrase is safe and effective in the treatment of acute cerebral infarction